Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan vs spironolactone + furosemide after partial hepatectomy for primary liver cancer with postoperative edema
ChiCTR-IPR-17011846Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tolvaptan in ascites, edema, hyponatraemia and 1 more (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoints: Abdominal circumference, B-ultrasound and 2 more. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
tolvaptan
03
Conditions
ascitesedemahyponatraemiaPrimary Hepatic Carcinoma (PHC)
Beyond the preview
Go deeper on ChiCTR-IPR-17011846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011846.